Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival

Author：                                

Publisher： Science Publishers

ISSN： 2049-9450

Source： Molecular and Clinical Oncology, Vol.3, Iss.5, 2015-01, pp. : 1053-1057

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Good response to leucovorin and fluorouracil plus oxaliplatin and cetuximab therapy in a patient with metastatic ascending colon cancer harboring a KRAS p.G13D mutation

By Ochiai Takumi   Nishimura Kazuhiko   Watanabe Tomoo   Kitajima Masayuki   Nakatani Akinori   Inou Takashi   Washio Marie   Sakuyama Naoki   Sato Tsuyoshi   Kishine Kenji   Ochi Takanori   Ookubo Satoshi   Futagawa Shunji   Orikasa Hideki   Mashiko Satomi   Nagaoka Isao  

Oncology Letters, Vol. 3, Iss. 2, 2012-02 ,pp. : 269-272

Spandidos Publications

Access to resources Recommend Favorite

Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer

By Hurvitz Sara   Lalla Deepa   Crosby Ross   Mathias Susan  

Breast Cancer Research and Treatment, Vol. 142, Iss. 3, 2013-12 ,pp. : 603-609

Springer Publishing Company

Access to resources Recommend Favorite

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer

By Soeda Hiroshi   Shimodaira Hideki   Watanabe Mika   Suzuki Takao   Gamoh Makio   Mori Takahiro   Komine Keigo   Iwama Noriyuki   Kato Shunsuke   Ishioka Chikashi  

International Journal of Clinical Oncology, Vol. 18, Iss. 4, 2013-08 ,pp. : 670-677

Springer Publishing Company

Access to resources Recommend Favorite

The Status of p53 in the Metastatic Progression of Colorectal Cancer

By Heide I.   Thiede C.   Sonntag T.   de Kant E.   Neubauer A.   Jonas S.   Peter F.J.   Neuhaus P.   Herrmann R.   Huhn D.   Rochlitz C.F.  

European Journal of Cancer, Vol. 33, Iss. 8, 1997-07 ,pp. : 1314-1322

Elsevier

Access to resources Recommend Favorite

Expression of E-cadherin and KRAS mutation may serve as biomarkers of cetuximab-based therapy in metastatic colorectal cancer

By                  

Oncology Letters, Vol. 5, Iss. 4, 2013-01 ,pp. : 1295-1300

Spandidos Publications

Access to resources Recommend Favorite